PDL BioPharma
Other · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $13.1M | $30.7M | $32.0M | $320.1M | $244.3M | $103.1M |
| Operating income | −$54.3M | −$51.1M | −$34.2M | $193.8M | $129.4M | $550.4M |
| Net income | −$31.7M | $6.7M | −$68.9M | $110.7M | $63.6M | $55.9M |
| Total assets | — | $717.2M | $963.7M | $1.24B | $1.22B | $1.01B |
| Total liabilities | — | $123.9M | $234.0M | $397.2M | $460.0M | $316.3M |
| Equity | $425.2M | $593.2M | $729.8M | $845.9M | $751.1M | $696.0M |
| EPS (diluted) | $-0.26 | $0.05 | $-0.47 | $0.71 | $0.39 | $0.34 |
| Shares out. | 123.6M | 128.1M | 153.8M | 165.6M | 164.3M | 162.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −415.0%
- Net margin
- −242.7%
- Return on equity
- −7.5%
- Return on assets
- —
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $3.44
- Revenue growth (YoY)
- −57.4%
- Net income growth (YoY)
- −574.9%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 9, 2020
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2017
- NT 10-Qmissed a reporting deadline ↗Aug 8, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreementDec 14, 2020
- Delisting / listing-standard notice · Director / officer changeDec 8, 2020
- Results of operations · Regulation FD disclosureNov 13, 2020
- Completed an acquisition or dispositionOct 7, 2020
- Entered a material agreement · Other material eventOct 2, 2020
- Regulation FD disclosureSep 10, 2020
- Other material eventSep 10, 2020
- Completed an acquisition or dispositionSep 9, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ASEC SCHEDULE 13GFeb 9, 2024
- SC 13G/ASEC SCHEDULE 13GFeb 10, 2023
- SC 13G/ASEC SCHEDULE 13GFeb 8, 2022
- 10-KMar 29, 2021
- SC TO-I/AFeb 19, 2021
- SC 13G/ASEC SCHEDULE 13GFeb 12, 2021
- SC 13G/AFeb 11, 2021
- SC 13G/AFeb 11, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
- EFFECTFeb 3, 2021
Corporate family
Spin-offs from PDL BioPharma (1)
- ABBOTT BIOTHERAPEUTICS CORPcompletedDec 18, 2008details
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.